|Articles|March 1, 2006
- Volume 0 0
Azithromycin for Injection
Advertisement
AmericanPharmaceuticalPartners(Schaumburg,Ill) recently receivedFDA approvalfor its abbreviatednew drug applicationfor Azithromycin forInjection. The product is the genericequivalent of Pfizer Inc's Zithromax.Azithromycin for Injection is indicated forthe treatment of community-acquiredpneumonia and pelvic inflammatory disease,when caused by susceptiblemicroorganisms. The product will beavailable in 500-mg vials. Azithromycinfor Injection is preservative-free, andeach vial will include a bar code andlatex-free vial stopper. For more information,visit www.appdrugs.com.
Articles in this issue
about 20 years ago
British Poll Shows People Denying Weight Problemsabout 20 years ago
Suing a Lawyer for Malpractice?about 20 years ago
Pharmacists—Cops or Not? (Part 1)about 20 years ago
Can You Read These Rxs?about 20 years ago
Alternative Measures for Treating Pediculosisabout 20 years ago
Compounding Hotlineabout 20 years ago
Obesity May Lead to Kidney Failureabout 20 years ago
Body Fat Associated with Alzheimer's Proteinabout 20 years ago
Midlife Obesity May Cause Heart Diseaseabout 20 years ago
The Evolution of Imprint IdentificationAdvertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
2
The CGM Data Point Pharmacists Should Always Check First
3
Early Oral Antiviral Use Associated With Lower Risk of Post–COVID-19 Condition, Study Finds
4
GLP-1s Are Associated With Reduced Asthma Exacerbation Risk in Nondiabetic Patients With Obesity
5